Drug Trial Radar · NCT00428948
Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,445
Actual
Start
Jan 2007
Primary completion
Jan 2012
Study completion Jan 2012
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- Collaborators
- Otsuka Pharmaceutical Co., Ltd.
- First posted
- Jan 30, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study's purpose is to evaluate the long-term safety and efficacy of tolvaptan versus placebo in patients with ADPKD.
Conditions
- Polycystic Kidney Disease, Autosomal Dominant
Interventions
TolvaptanDrug
Tolvaptan was supplied as tablets.
PlaceboDrug
Placebo was supplied as tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36Time frame: Baseline to Month 36
Locations
133 sites in 15 countries. Site status is shown where the registry gives one.
Coastal Clinical Research
Mobile, Alabama
University of South Alabama
Mobile, Alabama
Apex Research of Riverside
Riverside, California
Stanford University Medical Center
Stanford, California
University of Colorado Health Sciences Center
Denver, Colorado
Yale University School of Medicine
New Haven, Connecticut
Jacksonville Center for Clinical Research
Jacksonville, Florida
Coastal Nephrology Associates Research Center, LLC
Port Charlotte, Florida
Emory University School of Medicine
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Renal Associates of Baton Rough, L.L.C.
Baton Rouge, Louisiana
John Hopkins School of Medicine
Baltimore, Maryland
Tufts- New England Medical Center
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Mayo Medical Center
Rochester, Minnesota
Erie County Medical Center
Buffalo, New York
Nephrology Associates of Westchester
Hawthorne, New York
The Rogosin Institute
New York, New York
Columbia University Medical Center
New York, New York
University of North Carolina, UNC, Kidney Center
Chapel Hill, North Carolina
East Carolina University
Greenville, North Carolina
Kidney and Hypertension Center
Cincinnati, Ohio
University Hospitals of Cleveland/Case
Cleveland, Ohio
Northwest Renal Clinic, Inc.
Portland, Oregon
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
Charleston Nephrology Associates
Charleston, South Carolina
Nephrology Associates, P.C.
Nashville, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee
University of Virginia, Nephrology Clinical Research Center
Charlottesville, Virginia
Instituto de Nefrología, Nefrology SA
Buenos Aires, Argentina
Hospital Municipal de Vicente Lopez, Dr Bernardo Houssay
Buenos Aires, Argentina
Hosptial Universitario Austral
Buenos Aires, Argentina
Sanatorio Allende
Córdoba, Argentina
Hospital Privado-Centro Medico de Cordoba
Córdoba, Argentina
Royal Adelaide Hospital
Adelaide, Australia
Queen Elizebeth Hospital
Adelaide, Australia
Princess Alexandra Hospital
Brisbane, Australia
Royal Melbourne Hospital
Melbourne, Australia
Melbourne Renal Research Group
Melbourne, Australia
Showing 40 of 133 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.